Dr. Tim Coté is director of the FDA's Office of Orphan Products Development. Coté's office is responsible for implementing the 1983 Orphan Drug Act, originally the brainchild of a Connecticut woman whose children suffered from a rare disease. In the years since that Act was passed, says Coté, 357 new therapies have gone to full marketing approval and another 2,100 compounds that are "promising" have been labeled as orphan drugs. The Office of Orphan Product Development also serves as an ombudsman for everyone from patients groups to industry, expediting the development of drugs to fight approximately 7,000 rare diseases, including Gaucher's, Pompe's, Muscular Dystrophy, and Cystic Fibrosis -- diseases that affect roughly 30 million Americans. But while Coté sees progress in the battle against rare diseases, he adds:"Things can't expand fast enough for the people who really need [orphan drugs].... The single most important thing is that we have to hurry because people have children who need therapies right now."
Tim Coté on Orphan Drugs and the Fight Against Rare Diseases

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Dr. Tim Coté is director of the FDA's Office of Orphan Products Development. Coté's office is responsible for implementing the 1983 Orphan Drug Act, originally the brainchild of a Connecticut woman whose children suffered from a rare disease. In the years since that Act was passed, says Coté, 357 new therapies have gone to full marketing approval and another 2,100 compounds that are "promising" have been labeled as orphan drugs. The Office of Orphan Product Development also serves as an ombudsman for everyone from patients groups to industry, expediting the development of drugs to fight approximately 7,000 rare diseases, including Gaucher's, Pompe's, Muscular Dystrophy, and Cystic Fibrosis -- diseases that affect roughly 30 million Americans. But while Coté sees progress in the battle against rare diseases, he adds:"Things can't expand fast enough for the people who really need [orphan drugs].... The single most important thing is that we have to hurry because people have children who need therapies right now."
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
HF Management for Patients with Comorbid Conditions
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
Navigating Myasthenia Gravis in Adolescents and Young Adults
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?